4.7 Article

Ertapenem peritoneal fluid concentrations in adult surgical patients

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2008.09.015

关键词

Ertapenem; Peritoneal fluid; Intra-abdominal infections; Pharmacokinetics

资金

  1. MerckCo. Inc [102 A.20100.51900.R007]

向作者/读者索取更多资源

Ertapenem, a novel carbapenem, is approved for the treatment of mild to severe intra-abdominal infections (IAIs), although its in vivo concentrations in peritoneal fluid are unknown. The purpose of this study was to determine the peritoneal fluid concentration of ertapenem after a single 1 g intravenous dose. After informed consent, 21 patients (9 females and 12 males; mean +/- standard deviation (S. D.) age 50.2 +/- 17.7 years) requiring intra-abdominal surgery were enrolled. Plasma and peritoneal fluid samples were taken at fixed times during surgery. Drug concentrations were determined by high-performance liquid chromatography (HPLC) with ultraviolet detection. Mean +/- S. D. ertapenem peritoneal fluid concentrations were 64.3 +/- 23.4 mg/L at 1h and 31.3 +/- 26.5 mg/L at 3 h after administration. The mean tissue/plasma ratio ranged from 46.7% to 83.1%. The mean peritoneal fluid concentrations were well above the MIC(90) (minimum inhibitory concentration for 90% of the organisms) for susceptible bacteria found in IAIs, especially Escherichia coli, viridans streptococci, Enterobacteriaceae, Klebsiella spp. and Bacteroides fragilis, during the entire sampling time. These pharmacokinetic results support the assumption that ertapenem might be suitable for the treatment of IAIs. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据